Company: ADPT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103752
Chunk: 38

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 38
---
 |     | Immunocore Holdings plc       |     | Quanterix Corporation                   |
| BridgeBio Pharma, Inc.          |     | Invitae Corporation           |     | Recursion Pharmaceuticals, Inc.         |
| CareDx, Inc.                    |     | Myriad Genetics, Inc.         |     | Sage Therapeutics, Inc.                 |
| Fate Therapeutics, Inc.         |     | NanoString Technologies, Inc. |     | Twist Biosciences Corporation           |
| Guardant Health, Inc.           |     | Natera, Inc.                  |     | Veracyte, Inc.                          |

The compensation and human capital committee also referenced biotechnology and life science companies in the Radford McLagan Compensation Database when evaluating the competitiveness of our named executive officers’ target pay opportunities. For 2024, the compensation and human capital committee targeted the median percentile for base salary and bonus and used a fixed-share grant approach for equity compensation to manage dilution and share utilization concerns (which ultimately resulted in equity grants generally between the 25 thpercentile and median of our peer set). However, an executive officer’s established target pay level could be positioned above or below these levels based on individual factors, including but not limited to tenure in role, performance in role, company or business area performance and future leadership potential. The compensation and human capital committee undertook its annual review of the peer group in August 2024 to inform pay decisions for 2025. Several adjustments were made to the peer group in light of peer company bankruptcies, M&A activity, and size characteristics relative to Adaptive. As a result, seven companies were removed and six companies were added to the group. The following peer group will be referenced when considering pay for 2025:

| Allogene Therapeutics, Inc. |     | Immunocore Holdings plc                 |     | Quanterix Corporation           |
| bluebird bio, Inc.          |     | Maravai LifeSciences Holdings, Inc.     |     | Recursion Pharmaceuticals, Inc. |
| CareDx, Inc.                |     | Mesa Laboratories, Inc.                 |     | Sage Therapeutics, Inc.         |
| Castle Biosciences, Inc.    |     | Myriad Genetics, Inc.                   |     | Twist Bioscience Corporation    |
| Codexis, Inc.               |     | Natera, Inc.                            |     | Veracyte, Inc,                  |
| Fulgent Genetics, Inc.